Sedláková I, Laco J, Tošner J, Spaček J, Cermáková E
Ceska Gynekol. 2013 Dec;78(6):545-53.
To evaluate the correlation of drug resistance proteins LRP (Lung Resistance Protein), Pgp (P-glycoprotein), MRP1 (Multidrug Related Protein, Multidrug Resistance-Associated Protein), MRP3 a MRP5 with clinical - pathological factors and to find the clinical outcome of these data in ovarian cancer patients.
Prospective study.
Department of Obstetrics and Gynecology, Charles University in Prague, Faculty of Medicine and University Hospital Hradec Kralove.
111 patients with epithelial ovarian cancer who underwent primary surgery from 2006-2010 had specimens stained with imunohistochemistry for LRP, Pgp, MRP1, MRP3, MRP5.
The histological subtype of epithelial ovarian cancer correlated to the LRP, Pgp, MRP1 and MRP3 expression. Patients with late ovarian cancer had a higher MRP1 compared to early stage ovarian cancer (I+II 71.6% (CI 60-100), III+IV 83.6% (CI 100-100),p = 0.03). Correlation of MRP1 with grading was found(G1 60.83% (CI 10-100), G2 36.80% (CI 20-100),G3 88.87% (CI 100-100), p = 0.039). Patients with high Pgp, MRP1 and MRP3 expression had significantly shorter progression-free survival. (Kaplan-Meier test - PFS, Pgp < 85% Med PFS 23 months (CI 8-37) vs > 85% Med PFS 11 months (CI 7-17), p = 0.054), (MRP1 < 85% Med PFS 33 months (CI 11-49) vs > 85% Med PFS 11 months(CI 7-16), p = 0.046).
We found clinical significance of LRP, Pgp, MRP1 and MRP3 expression in ovarian cancer patients. MRP5 expression did not correlate with neither histo-pathological parameters nor progression free survival. MRP1 have some additional predictive and prognostic value for the clinical outcome of patients with ovarian carcinoma.
评估耐药蛋白LRP（肺耐药蛋白）、Pgp（P-糖蛋白）、MRP1（多药相关蛋白）、MRP3和MRP5与临床病理因素的相关性，并探讨这些数据在卵巢癌患者中的临床结局。
前瞻性研究。
布拉格查理大学医学院妇产科及赫拉德茨克拉洛韦大学医院。
对2006年至2010年接受初次手术的111例上皮性卵巢癌患者的标本进行LRP、Pgp、MRP1、MRP3、MRP5免疫组织化学染色。
上皮性卵巢癌的组织学亚型与LRP、Pgp、MRP1和MRP3的表达相关。晚期卵巢癌患者的MRP1表达高于早期卵巢癌患者（I+II期71.6%（CI 60-100），III+IV期83.6%（CI 100-100），p = 0.03）。发现MRP1与分级相关（G1级60.83%（CI 10-100），G2级36.80%（CI 20-100），G3级88.87%（CI 100-100），p = 0.039）。Pgp、MRP1和MRP3高表达的患者无进展生存期明显较短。（Kaplan-Meier检验 - 无进展生存期，Pgp < 85% 中位无进展生存期23个月（CI 8-37） vs > 85% 中位无进展生存期11个月（CI 7-17），p = 0.054），（MRP1 < 85% 中位无进展生存期33个月（CI 11-49） vs > 85% 中位无进展生存期11个月（CI 7-16），p = 0.046）。
我们发现LRP、Pgp、MRP1和MRP3在卵巢癌患者中的表达具有临床意义。MRP5的表达与组织病理学参数及无进展生存期均无相关性。MRP1对卵巢癌患者的临床结局具有一定的额外预测和预后价值。
